152 related articles for article (PubMed ID: 16683304)
1. Seeing the big picture.
Hoag H
Nature; 2006 Apr; 440(7087):1084-5. PubMed ID: 16683304
[No Abstract] [Full Text] [Related]
2. The brains behind blockbusters.
Couzin J
Science; 2005 Jul; 309(5735):728. PubMed ID: 16051786
[No Abstract] [Full Text] [Related]
3. Drug hunt.
Hoag H
Nature; 2006 Feb; 439(7078):886-7. PubMed ID: 16506321
[No Abstract] [Full Text] [Related]
4. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
5. Biomedical research: Drug hunters wanted.
Perkel JM
Nature; 2015 Aug; 524(7564):257-8. PubMed ID: 26273714
[No Abstract] [Full Text] [Related]
6. Pharma moves ahead cautiously in China.
Yidong G
Science; 2005 Jul; 309(5735):735. PubMed ID: 16051788
[No Abstract] [Full Text] [Related]
7. Translational medicine 2006.
Persiani S
IDrugs; 2006 Apr; 9(4):253-5. PubMed ID: 16596476
[No Abstract] [Full Text] [Related]
8. Extrapolation of preclinical data into clinical reality translational science.
Singer T
Ernst Schering Res Found Workshop; 2007; (59):1-5. PubMed ID: 17117711
[TBL] [Abstract][Full Text] [Related]
9. Hit and Lead identification: efficient practices for drug discovery.
Goodnow RA; Gillespie P
Prog Med Chem; 2007; 45():1-61. PubMed ID: 17280901
[No Abstract] [Full Text] [Related]
10. Scripps Florida.
Sheppard TL
Nat Chem Biol; 2007 Aug; 3(8):451. PubMed ID: 17637772
[TBL] [Abstract][Full Text] [Related]
11. High throughput screening: early successes indicate a promising future.
Fox S; Wang H; Sopchak L; Khoury R
J Biomol Screen; 2001 Jun; 6(3):137-40. PubMed ID: 11689109
[No Abstract] [Full Text] [Related]
12. Pharma goes to work. Introduction.
Mervis J
Science; 2005 Jul; 309(5735):721. PubMed ID: 16051780
[No Abstract] [Full Text] [Related]
13. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
14. Financial interests constrain drug development.
Garattini S
Science; 1997 Jan; 275(5298):287. PubMed ID: 9005546
[No Abstract] [Full Text] [Related]
15. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
16. When Pharma merges, R&D is the dowry.
Agnew B
Science; 2000 Mar; 287(5460):1952-3. PubMed ID: 10755948
[No Abstract] [Full Text] [Related]
17. Forging synergies in drug discovery.
Nat Chem Biol; 2008 Feb; 4(2):83. PubMed ID: 18202672
[No Abstract] [Full Text] [Related]
18. MRI in preclinical drug development.
Silva MD; Chandra S
Methods Mol Med; 2006; 124():299-322. PubMed ID: 16506427
[TBL] [Abstract][Full Text] [Related]
19. Contract investigators.
Ledford H
Nature; 2010 Jul; 466(7303):280-1. PubMed ID: 20695121
[No Abstract] [Full Text] [Related]
20. Toward biosimilar monoclonal antibodies.
Schneider CK; Kalinke U
Nat Biotechnol; 2008 Sep; 26(9):985-90. PubMed ID: 18779806
[No Abstract] [Full Text] [Related]
[Next] [New Search]
